The Global Anti-neoplastic Agents Market size is estimated to grow at a CAGR of 8.3% from 2021 to 2026.
Anti-neoplastic agents are drugs that are used as the primary treatment of patients who have cancer. Anti-neoplastic is a variety of medicine to limit or kill tumor cells in the body. It plays a vital role in comprehensive cancer therapy, especially for disseminated tumor and leukemia that cannot be treated with surgery.
MARKET DRIVERS
Increasing incidences of cancer cases, increasing funding from government bodies, technological advancements, and favorable reimbursement policies are significant factors boosting the anti-neoplastic agents market growth.
Anti-neoplastic agents are primarily utilized along with immunotherapy, surgery, hormone therapy, radiotherapy, and targeted therapy for several solid tumors, particularly metastatic. The danger associated with cancer increases along with age, and it is now growing common across the globe due to the quickly changing standard of living of individuals. Therefore, increasing demand and requirement for anti-neoplastic agents have attracted several major pharmaceutical market players to enter the global anti-neoplastic agents market and expand more competent drugs against numerous cancer conditions.
According to the Center for Disease Control and Prevention (CDC), malignant neoplasms accounted for 15% of deaths across the world, with 19.3 million new cases of cancer is considered to be diagnosed by 2025. As a paradigm, the reports according to the Healthcare Cost and Utilization Project (H-cup), there were 4.7 million hospitalizations associated with cancer in the U.S., and around 6% of the adult population of inpatient hospital cost was caused due to hospitalization of patients with cancer.
Additionally, advanced technologies that are used up in the anti-neoplastic agents market are one such factor that propels the Anti-neoplastic Agents Market growth. Also, private organizations' investments for the manufacturing of drugs related to cancer and other diseases are accelerating market growth. Growing requirements for the anti-neoplastic pharmaceutical agents that have dragged pharmaceutical industries' attention to get into the market for developing and manufacturing more productive drugs for fighting cancer conditions drive the market growth.
MARKET RESTRAINTS
Absenteeism of preset the regulatory frameworks that are considerably hampering the market growth. Moreover, some adverse effects that will be raised that are associated with neoplastic agents are to hinder the market growth. For example, strict rules to follow by the top companies in producing drugs are likely to obstruct market growth. Also, the need for FDA approvals for the drug release into the market is restraining the Anti-neoplastic Agents Market growth.
Lack of knowledge about cancer in people is impeding market growth. The diverse nature of cancer and the cost related to the development are high, limiting the growth. Technical Complications that are related to the existing diagnostic tests are the factors that restrain the Anti-neoplastic Agents Market growth.
Impact of COVID-19 on Anti-Neoplastic Agents Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries worldwide, with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Antineoplastic Interferon Drug market in 2020.
COVID-19 can influence the global economy in three ways: by directly hitting production and demand, by causing supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has affected many aspects, like restrictions on flight travel and all indoor events restricted, falling business confidence, growing panic among the population, and uncertainty about the future.
As the different regions' governments have already announced a complete lockdown and temporary closedown of industries, there is a significant loss for the companies, hindering the market's growth rate.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By-Products, End Users, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the Global Anti-neoplastic Agents Market segmented and sub-segmented based on the products, end-users, and region.
Anti-neoplastic Agents Market – By Product:
Based on the product, the chemotherapeutic agent segment accounts for a significant share of the market revenue. The chemotherapeutic agents' segment is foreseen to lead the market due to the easy availability of drugs. The immunotherapeutic agents' segment is expected to proliferate due to increasing biological therapy acceptance due to lesser side effects.
Anti-neoplastic Agents Market – By End Users:
Based on end-users, the Hospital segment dominated a significant share of the market revenue. The hospital end-user portion is expected to provide the highest share among end-users. As per the statistics given by The Healthcare Cost and Utilization Project, there were 4.7 Mn hospital admissions related to cancer in the U.S. in 2009. The hospital admission of cancer patients formed about 6% of adult inpatient hospital costs.
Anti-neoplastic Agents Market – By Region:
Geographically, the Global Anti-neoplastic Agents market was dominated by North America closely followed Europe. Asia Pacific is expected to grow at a high CAGR.
North America region is dominating and is holding the largest share of the anti-neoplastic agents market. Due to the standard increase of contagious diseases, the appearance of highly developed healthcare is some of the factors that drive this region forward. North America has a vital contribution to the leading market standing. It is estimated to help sustain the market share over the forecast period, due to the advanced healthcare infrastructure and facilities, government investment, and the generally followed unhealthy lifestyle of the consumers leading to chronic diseases.
Europe is the second-largest and second-leading region in the global anti-neoplastic agents market and follows closely behind North America in the worldwide market share. The U.K. and Germany contribute the highest shares of the market with the awareness of anti-neoplastic agents and a growing economy. According to the Cancer Research of UK, 605 people per 100,000 general populations are diagnosed with cancer. In this region, countries like the UK and Germany are considered to notice high acceptance for anti-cancer drugs compared with others.
Asia Pacific region is expected to be the fastest-growing region in the anti-neoplastic agents market. Japan, India, and China are with the highest shares of the market. Factors such as rising dis, awareness of the advantages of early diagnosis, improving the posable income, escalating expenditure on the healthcare sector are projected to drive the anti-neoplastic agents market. In this region, countries like Japan and Australia are considered to have favorable market development. China and India are considered the most attractive market due to the high incidences of the syndrome and crucial market players' existence.
The middle east and Africa regions are expected to see a slow and gradual market growth due to lack of awareness about optimal healthcare and anti-neoplastic agents and lack of skilled expertise towards cancer cure and medical treatments.
KEY MARKET PARTICIPANTS:
Some of the top companies leading the Global Anti-neoplastic Agents Market profiled in this report are Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, and AbbVie Inc.
Genentech, one of the top leading companies, has been approved by the FDA to accept atezolizumab that is the treatment used by the patient suffering from metastatic non-small lung cancer for those whose tumor is high with PD-L1 expression.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Chemotherapeutic agent
5.1.3 Biological agents
5.1.4 Personalied medicine
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 End user
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Clinics
5.2.4 Cancer rehabilitaion centers
5.2.5 Ambulatory surgical centers
5.2.6 Y-o-Y Growth Analysis, By end user
5.2.7 Market Attractiveness Analysis, By end user
5.2.8 Market Share Analysis, By end user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By end user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By end user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By end user
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen Inc.
8.3 Bristol-Myers Squibb Company
8.4 Baxter Healthcare Corporation
8.5 Boehringer Ingelheim GmbH
8.6 Aspen Global Inc.
8.7 Bayer AG
8.8 Teva pharmaceutical Industries Ltd.
8.9 Johnson & Johnson Pvt. Ltd.
8.10 Accord Healthcare, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
